{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T09:41:02Z","timestamp":1792748462237,"version":"4.5.0"},"reference-count":167,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biological Psychiatry Global Open Science"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.bpsgos.2026.100793","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T07:04:45Z","timestamp":1784790285000},"page":"100793","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["GLP-1 Receptor Agonist and GIP\/GLP-1 Receptor Dual Agonist Therapeutics at the Intersection of Alcohol Use Disorder, Obesity, and Cardiometabolic Dysfunction"],"prefix":"10.1016","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-1041-6602","authenticated-orcid":false,"given":"Joshua","family":"Reitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel B.","family":"Rosoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pal","family":"Pacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0480-7755","authenticated-orcid":false,"given":"Falk W.","family":"Lohoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bpsgos.2026.100793_bib1","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/S0140-6736(18)31310-2","article-title":"Alcohol use and burden for 195 countries and territories, 1990\u20132016: A systematic analysis for the Global Burden of Disease Study 2016","volume":"392","author":"Griswold","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.bpsgos.2026.100793_bib2","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12937-025-01082-z","article-title":"Burden of diseases attributable to excess body weight in 204 countries and territories, 1990\u20132019","volume":"24","author":"Safiri","year":"2025","journal-title":"Nutr J"},{"key":"10.1016\/j.bpsgos.2026.100793_bib3","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1038\/s41598-022-06010-3","article-title":"Prevalence and associations of metabolic syndrome in patients with alcohol use disorder","volume":"12","author":"Hern\u00e1ndez-Rubio","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.bpsgos.2026.100793_bib4","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/alcalc\/agw040","article-title":"The prevalence of metabolic syndrome in alcohol use disorders: A systematic review and meta-analysis","volume":"51","author":"Vancampfort","year":"2016","journal-title":"Alcohol"},{"key":"10.1016\/j.bpsgos.2026.100793_bib5","article-title":"Burden of high-risk phenotype of heavy alcohol consumption among obese U.S. population: Results from National Health and Nutrition Examination Survey, 1999","volume":"23","author":"Raza","year":"2023","journal-title":"The Lancet Regional Health"},{"key":"10.1016\/j.bpsgos.2026.100793_bib6","doi-asserted-by":"crossref","first-page":"5938","DOI":"10.1038\/s41380-025-03259-8","article-title":"Crosstalk between alcohol use disorder and obesity: Two sides of the same coin?","volume":"30","author":"Leggio","year":"2025","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.bpsgos.2026.100793_bib7","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1055\/s-0040-1701443","article-title":"Drinking and obesity: Alcoholic liver disease\/nonalcoholic fatty liver disease interactions","volume":"40","author":"\u00c5berg","year":"2020","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.bpsgos.2026.100793_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.alcohol.2020.07.010","article-title":"Moderate alcohol consumption is not associated with subclinical cardiovascular damage but with hepatic fibrosis in non-alcoholic fatty liver disease","volume":"89","author":"Kashiwagi","year":"2020","journal-title":"Alcohol"},{"key":"10.1016\/j.bpsgos.2026.100793_bib9","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.gande.2025.01.003","article-title":"Alcohol-associated liver disease: A review","volume":"3","author":"Nagarjuna","year":"2025","journal-title":"Gastroenterol Endosc"},{"key":"10.1016\/j.bpsgos.2026.100793_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2022.1042442","article-title":"Non-alcoholic fatty liver disease (NAFLD) and mental illness: Mechanisms linking mood, metabolism and medicines","volume":"16","author":"Gangopadhyay","year":"2022","journal-title":"Front Neurosci"},{"key":"10.1016\/j.bpsgos.2026.100793_bib11","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.2147\/DMSO.S540103","article-title":"Obesity and its comorbidities: Current treatment options, emerging biological mechanisms, future perspectives and challenges","volume":"18","author":"Wang","year":"2025","journal-title":"Diabetes Metab Syndr Obes"},{"key":"10.1016\/j.bpsgos.2026.100793_bib12","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/j.cgh.2018.11.033","article-title":"Effects of alcohol consumption and metabolic syndrome on mortality in patients with nonalcoholic and alcohol-related fatty liver disease","volume":"17","author":"Younossi","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.bpsgos.2026.100793_bib13","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.jhep.2023.03.017","article-title":"Global burden of liver disease: 2023 update","volume":"79","author":"Devarbhavi","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.bpsgos.2026.100793_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2022.767506","article-title":"Targeting unmet clinical needs in the treatment of alcohol use disorder","volume":"13","author":"Lohoff","year":"2022","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.bpsgos.2026.100793_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2025.108957","article-title":"Treatment approaches for alcohol use disorder with metabolic dysfunction","volume":"277","author":"Wagner","year":"2026","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.bpsgos.2026.100793_bib16","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1001\/jama.2018.11406","article-title":"Diagnosis and pharmacotherapy of alcohol use disorder: A review","volume":"320","author":"Kranzler","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.bpsgos.2026.100793_bib17","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s13300-020-00981-0","article-title":"The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of type 2 diabetes: The SurPASS clinical trials","volume":"12","author":"Min","year":"2021","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.bpsgos.2026.100793_bib18","doi-asserted-by":"crossref","first-page":"25","DOI":"10.7570\/jomes22067","article-title":"Efficacy and safety of tirzepatide in type 2 diabetes and obesity management","volume":"32","author":"Sinha","year":"2023","journal-title":"J Obes Metab Syndr"},{"key":"10.1016\/j.bpsgos.2026.100793_bib19","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for metabolic dysfunction\u2013associated steatohepatitis with liver fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bpsgos.2026.100793_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.838410","article-title":"Recent advances in incretin-based pharmacotherapies for the treatment of obesity and diabetes","volume":"13","author":"Tan","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.bpsgos.2026.100793_bib21","doi-asserted-by":"crossref","DOI":"10.1111\/bcpt.70004","article-title":"Effects of GLP-1 receptor agonists in alcohol use disorder","volume":"136","author":"Klausen","year":"2025","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.bpsgos.2026.100793_bib22","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1038\/s41591-023-02634-8","article-title":"GLP-1 receptor agonists are promising but unproven treatments for alcohol and substance use disorders","volume":"29","author":"Leggio","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.bpsgos.2026.100793_bib23","doi-asserted-by":"crossref","DOI":"10.1017\/neu.2025.6","article-title":"A systematic review on the role of glucagon-like peptide-1 receptor agonists on alcohol-related behaviors: Potential therapeutic strategy for alcohol use disorder","volume":"37","author":"Zheng","year":"2025","journal-title":"Acta Neuropsychiatr"},{"key":"10.1016\/j.bpsgos.2026.100793_bib24","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","article-title":"Biology of incretins: GLP-1 and GIP","volume":"132","author":"Baggio","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpsgos.2026.100793_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2022.170749","article-title":"GLP-1 and GIP receptor signaling in beta cells\u2014A review of receptor interactions and co-stimulation","volume":"151","author":"Mayendraraj","year":"2022","journal-title":"Peptides"},{"key":"10.1016\/j.bpsgos.2026.100793_bib26","doi-asserted-by":"crossref","first-page":"5338","DOI":"10.3390\/ijms26115338","article-title":"GLP-1 analogues in the neurobiology of addiction: Translational insights and therapeutic perspectives","volume":"26","author":"Marquez-Meneses","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bpsgos.2026.100793_bib27","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nrn.2018.8","article-title":"Signalling from the periphery to the brain that regulates energy homeostasis","volume":"19","author":"Kim","year":"2018","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.bpsgos.2026.100793_bib28","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: Mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.bpsgos.2026.100793_bib29","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/bph.15576","article-title":"The role of nucleus of the solitary tract glucagon-like peptide-1 and prolactin-releasing peptide neurons in stress: Anatomy, physiology and cellular interactions","volume":"179","author":"Holt","year":"2022","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bpsgos.2026.100793_bib30","doi-asserted-by":"crossref","first-page":"3304","DOI":"10.3390\/nu12113304","article-title":"Glucagon-like Peptide-1 (GLP-1) in the integration of neural and endocrine responses to stress","volume":"12","author":"Diz-Chaves","year":"2020","journal-title":"Nutrients"},{"key":"10.1016\/j.bpsgos.2026.100793_bib31","first-page":"843","article-title":"Bidirectional interactions between the gut microbiota and incretin-based therapies","volume":"15","author":"Trapanese","year":"2025","journal-title":"Life (Basel)"},{"key":"10.1016\/j.bpsgos.2026.100793_bib32","doi-asserted-by":"crossref","DOI":"10.1172\/JCI194751","article-title":"Antiinflammatory actions of glucagon-like peptide-1\u2013based therapies beyond metabolic benefits","volume":"135","author":"Wong","year":"2025","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bpsgos.2026.100793_bib33","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1038\/s41586-026-10444-4","article-title":"A brain reward circuit inhibited by next-generation weight-loss drugs in mice","volume":"654","author":"Godschall","year":"2026","journal-title":"Nature"},{"key":"10.1016\/j.bpsgos.2026.100793_bib34","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1210\/en.2009-0220","article-title":"Minireview: Finding the sweet spot: Peripheral versus central glucagon-like peptide 1 action in feeding and glucose homeostasis","volume":"150","author":"Williams","year":"2009","journal-title":"Endocrinology"},{"key":"10.1016\/j.bpsgos.2026.100793_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2024.171179","article-title":"GLP1R and GIPR expression and signaling in pancreatic alpha cells, beta cells and delta cells","volume":"175","author":"Shilleh","year":"2024","journal-title":"Peptides"},{"key":"10.1016\/j.bpsgos.2026.100793_bib36","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1172\/JCI116186","article-title":"Preserved incretin activity of glucagon-like peptide 1 [7\u201336 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus","volume":"91","author":"Nauck","year":"1993","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bpsgos.2026.100793_bib37","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.regpep.2006.07.007","article-title":"The elimination rates of intact GIP as well as its primary metabolite, GIP 3\u201342, are similar in type 2 diabetic patients and healthy subjects","volume":"137","author":"Vilsb\u00f8ll","year":"2006","journal-title":"Regul Pept"},{"key":"10.1016\/j.bpsgos.2026.100793_bib38","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1210\/endo.139.9.6288","article-title":"Functional GIP receptors are present on adipocytes","volume":"139","author":"Yip","year":"1998","journal-title":"Endocrinology"},{"key":"10.1016\/j.bpsgos.2026.100793_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2025.102118","article-title":"Glucose-dependent insulinotropic polypeptide (GIP)","volume":"95","author":"M\u00fcller","year":"2025","journal-title":"Mol Metab"},{"key":"10.1016\/j.bpsgos.2026.100793_bib40","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.cmet.2019.07.013","article-title":"Glucose-dependent insulinotropic polypeptide receptor-expressing cells in the hypothalamus regulate food intake","volume":"30","author":"Adriaenssens","year":"2019","journal-title":"Cell Metab"},{"key":"10.1016\/j.bpsgos.2026.100793_bib41","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.164921","article-title":"Hypothalamic and brainstem glucose-dependent insulinotropic polypeptide receptor neurons employ distinct mechanisms to affect feeding","volume":"8","author":"Adriaenssens","year":"2023","journal-title":"JCI Insight"},{"key":"10.1016\/j.bpsgos.2026.100793_bib42","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/nm727","article-title":"Inhibition of gastric inhibitory polypeptide signaling prevents obesity","volume":"8","author":"Miyawaki","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/j.bpsgos.2026.100793_bib43","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/j.cmet.2023.07.010","article-title":"GIPR\/GLP-1R dual agonist therapies for diabetes and weight loss-Chemistry, physiology, and clinical applications","volume":"35","author":"Campbell","year":"2023","journal-title":"Cell Metab"},{"key":"10.1016\/j.bpsgos.2026.100793_bib44","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1016\/j.cmet.2024.05.010","article-title":"Tirzepatide modulates the regulation of adipocyte nutrient metabolism through long-acting activation of the GIP receptor","volume":"36","author":"Regmi","year":"2024","journal-title":"Cell Metab"},{"key":"10.1016\/j.bpsgos.2026.100793_bib45","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.cmet.2024.11.003","article-title":"The GIP receptor activates futile calcium cycling in white adipose tissue to increase energy expenditure and drive weight loss in mice","volume":"37","author":"Yu","year":"2025","journal-title":"Cell Metab"},{"key":"10.1016\/j.bpsgos.2026.100793_bib46","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.ejphar.2010.10.059","article-title":"Prolonged GIP receptor activation improves cognitive function, hippocampal synaptic plasticity and glucose homeostasis in high-fat fed mice","volume":"650","author":"Porter","year":"2011","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.bpsgos.2026.100793_bib47","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1152\/jn.00866.2010","article-title":"Glucose-dependent insulinotropic polypeptide receptor knockout mice are impaired in learning, synaptic plasticity, and neurogenesis","volume":"105","author":"Faivre","year":"2011","journal-title":"J Neurophysiol"},{"key":"10.1016\/j.bpsgos.2026.100793_bib48","article-title":"GIP-overexpressing mice demonstrate reduced diet-induced obesity and steatosis, and improved glucose homeostasis","volume":"7","author":"Kim","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.bpsgos.2026.100793_bib49","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/bph.15677","article-title":"The role of glucagon-like peptide 1 (GLP-1) in addictive disorders","volume":"179","author":"Klausen","year":"2022","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bpsgos.2026.100793_bib50","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.tem.2024.07.022","article-title":"The unexpected role of GIP in transforming obesity treatment","volume":"36","author":"Zandvakili","year":"2025","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.bpsgos.2026.100793_bib51","article-title":"What combines best with GLP-1 for obesity treatment: GIP receptor agonists or antagonists?","volume":"2","author":"Holst","year":"2021","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.bpsgos.2026.100793_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110953","article-title":"A brainstem circuit for nausea suppression","volume":"39","author":"Zhang","year":"2022","journal-title":"Cell Rep"},{"key":"10.1016\/j.bpsgos.2026.100793_bib53","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1111\/dom.15216","article-title":"The importance of glucose-dependent insulinotropic polypeptide receptor activation for the effects of tirzepatide","volume":"25","author":"Gasbjerg","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.bpsgos.2026.100793_bib54","doi-asserted-by":"crossref","DOI":"10.1172\/JCI146353","article-title":"GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice","volume":"131","author":"Samms","year":"2021","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bpsgos.2026.100793_bib55","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.140532","article-title":"Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist","volume":"5","author":"Willard","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.bpsgos.2026.100793_bib56","doi-asserted-by":"crossref","first-page":"155","DOI":"10.35946\/arcr.v35.2.06","article-title":"Chronic diseases and conditions related to alcohol use","volume":"35","author":"Shield","year":"2013","journal-title":"Alcohol Res"},{"key":"10.1016\/j.bpsgos.2026.100793_bib57","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1093\/ije\/dyw175","article-title":"Metabolic profiling of alcohol consumption in 9778 young adults","volume":"45","author":"W\u00fcrtz","year":"2016","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.bpsgos.2026.100793_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.jnha.2025.100539","article-title":"The effects of wine consumption and lipid profile: A systematic review and meta-analysis of clinical trials","volume":"29","author":"Lucer\u00f3n-Lucas-Torres","year":"2025","journal-title":"J Nutr Health Aging"},{"key":"10.1016\/j.bpsgos.2026.100793_bib59","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.5844","article-title":"Association of high-intensity binge drinking with lipid and liver function enzyme levels","volume":"2","author":"Rosoff","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.bpsgos.2026.100793_bib60","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.008202","article-title":"Sex-specific associations between alcohol consumption and incidence of hypertension: A systematic review and meta-analysis of cohort studies","volume":"7","author":"Roerecke","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.bpsgos.2026.100793_bib61","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1161\/CIR.0000000000001341","article-title":"Alcohol use and cardiovascular disease: A scientific statement from the American Heart Association","volume":"152","author":"Piano","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.bpsgos.2026.100793_bib62","doi-asserted-by":"crossref","DOI":"10.1111\/adb.70128","article-title":"Alcohol use disorder with metabolic dysfunction is associated with adverse health impacts in a United States clinical setting","volume":"31","author":"Wagner","year":"2026","journal-title":"Addict Biol"},{"key":"10.1016\/j.bpsgos.2026.100793_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.ynstr.2025.100713","article-title":"Gut Microbiome-Liver-Brain axis in Alcohol Use Disorder. The role of gut dysbiosis and stress in alcohol-related cognitive impairment progression: Possible therapeutic approaches","volume":"35","author":"Pich","year":"2025","journal-title":"Neurobiol Stress"},{"key":"10.1016\/j.bpsgos.2026.100793_bib64","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003410","article-title":"Evaluating the relationship between alcohol consumption, tobacco use, and cardiovascular disease: A multivariable Mendelian randomization study","volume":"17","author":"Rosoff","year":"2020","journal-title":"PLOS Med"},{"key":"10.1016\/j.bpsgos.2026.100793_bib65","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1007\/s13679-014-0129-4","article-title":"Alcohol consumption and obesity: An update","volume":"4","author":"Traversy","year":"2015","journal-title":"Curr Obes Rep"},{"key":"10.1016\/j.bpsgos.2026.100793_bib66","doi-asserted-by":"crossref","first-page":"30","DOI":"10.2133\/dmpk.DMPK-10-RV-087","article-title":"Progression of alcoholic and non-alcoholic steatohepatitis: Common metabolic aspects of innate immune system and oxidative stress","volume":"26","author":"Sakaguchi","year":"2011","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1016\/j.bpsgos.2026.100793_bib67","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1186\/s12967-023-04166-8","article-title":"Pathogenic mechanisms and regulatory factors involved in alcoholic liver disease","volume":"21","author":"Yan","year":"2023","journal-title":"J Transl Med"},{"key":"10.1016\/j.bpsgos.2026.100793_bib68","doi-asserted-by":"crossref","DOI":"10.1172\/JCI176345","article-title":"Alcohol-associated liver disease","volume":"134","author":"Mackowiak","year":"2024","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bpsgos.2026.100793_bib69","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1042\/CS20220572","article-title":"Molecular mechanisms of metabolic associated fatty liver disease (MAFLD): Functional analysis of lipid metabolism pathways","volume":"136","author":"Badmus","year":"2022","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.bpsgos.2026.100793_bib70","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.14309\/ajg.0000000000000340","article-title":"Alcohol consumption and risk of liver cirrhosis: A systematic review and meta-analysis","volume":"114","author":"Roerecke","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.bpsgos.2026.100793_bib71","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.cld.2013.09.006","article-title":"The impact of obesity and metabolic syndrome on alcoholic liver disease","volume":"18","author":"Chiang","year":"2014","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.bpsgos.2026.100793_bib72","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1111\/dar.13286","article-title":"The role of alcohol use in the aetiology and progression of liver disease: A narrative review and a quantification","volume":"40","author":"Rehm","year":"2021","journal-title":"Drug Alcohol Rev"},{"key":"10.1016\/j.bpsgos.2026.100793_bib73","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jhep.2022.08.030","article-title":"Alcohol consumption and metabolic syndrome: Clinical and epidemiological impact on liver disease","volume":"78","author":"\u00c5berg","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.bpsgos.2026.100793_bib74","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.170671","article-title":"The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission","volume":"8","author":"Chuong","year":"2023","journal-title":"JCI Insight"},{"key":"10.1016\/j.bpsgos.2026.100793_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104642","article-title":"Semaglutide reduces alcohol intake and relapse-like drinking in male and female rats","volume":"93","author":"Aran\u00e4s","year":"2023","journal-title":"EBiomedicine"},{"key":"10.1016\/j.bpsgos.2026.100793_bib76","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0061965","article-title":"Gut peptide GLP-1 and its analogue, exendin-4, decrease alcohol intake and reward","volume":"8","author":"Shirazi","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.bpsgos.2026.100793_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107312","article-title":"IUPHAR review\u2014Glucagon-like peptide-1 (GLP-1) and substance use disorders: An emerging pharmacotherapeutic target","volume":"207","author":"Bruns Vi","year":"2024","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.bpsgos.2026.100793_bib78","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.159863","article-title":"Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial","volume":"7","author":"Klausen","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.bpsgos.2026.100793_bib79","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/FBP.0000000000000609","article-title":"Glucagon-like peptide-1 receptor agonist, exendin-4, reduces reinstatement of heroin-seeking behavior in rats","volume":"32","author":"Douton","year":"2021","journal-title":"Behav Pharmacol"},{"key":"10.1016\/j.bpsgos.2026.100793_bib80","doi-asserted-by":"crossref","first-page":"e583","DOI":"10.1038\/tp.2015.68","article-title":"The glucagon-like peptide-1 receptor as a potential treatment target in alcohol use disorder: Evidence from human genetic association studies and a mouse model of alcohol dependence","volume":"5","author":"Suchankova","year":"2015","journal-title":"Transl Psychiatry"},{"key":"10.1016\/j.bpsgos.2026.100793_bib81","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-17190-3","article-title":"Differential association between the GLP1R gene variants and brain functional connectivity according to the severity of alcohol use","volume":"12","author":"Farokhnia","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.bpsgos.2026.100793_bib82","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1038\/mp.2017.153","article-title":"Genome-wide association study of alcohol consumption and genetic overlap with other health-related traits in UK Biobank (N=112 117)","volume":"22","author":"Clarke","year":"2017","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.bpsgos.2026.100793_bib83","doi-asserted-by":"crossref","first-page":"3184","DOI":"10.1038\/s41591-023-02653-5","article-title":"Multi-ancestry study of the genetics of problematic alcohol use in over 1 million individuals","volume":"29","author":"Zhou","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.bpsgos.2026.100793_bib84","article-title":"Semaglutide: A Promising Treatment for Alcohol Use Disorder","author":"Patton","year":"2023","journal-title":"Preprints.org"},{"key":"10.1016\/j.bpsgos.2026.100793_bib85","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1001\/jamapsychiatry.2024.3599","article-title":"Repurposing semaglutide and liraglutide for alcohol use disorder","volume":"82","author":"L\u00e4hteenvuo","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.bpsgos.2026.100793_bib86","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1038\/s41467-024-48780-6","article-title":"Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population","volume":"15","author":"Wang","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.bpsgos.2026.100793_bib87","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1111\/apt.70007","article-title":"Impact of GLP-1 receptor agonists on alcohol-related liver disease development and progression in alcohol use disorder","volume":"61","author":"Kuo","year":"2025","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.bpsgos.2026.100793_bib88","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000561","article-title":"Transforming steatotic liver disease management: The emerging role of GLP-1 receptor agonists","volume":"8","author":"Jensen","year":"2024","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.bpsgos.2026.100793_bib89","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.170419","article-title":"Effects of dulaglutide on alcohol consumption during smoking cessation","volume":"8","author":"Probst","year":"2023","journal-title":"JCI Insight"},{"key":"10.1016\/j.bpsgos.2026.100793_bib90","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1001\/jamapsychiatry.2024.4789","article-title":"Once-weekly semaglutide in adults with alcohol use disorder: A randomized clinical trial","volume":"82","author":"Hendershot","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.bpsgos.2026.100793_bib91","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(26)00305-3","article-title":"Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: A randomised, double-blind, placebo-controlled trial","volume":"407","author":"Klausen","year":"2026","journal-title":"Lancet"},{"key":"10.1016\/j.bpsgos.2026.100793_bib92","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1007\/s00213-025-06854-3","article-title":"Semaglutide, tirzepatide, and Retatrutide attenuate the interoceptive effects of alcohol in male and female rats","volume":"243","author":"Windram","year":"2025","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.bpsgos.2026.100793_bib93","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2022.908948","article-title":"Genetic variability of incretin receptors and alcohol dependence: A pilot study","volume":"15","author":"Tsermpini","year":"2022","journal-title":"Front Mol Neurosci"},{"key":"10.1016\/j.bpsgos.2026.100793_bib94","doi-asserted-by":"crossref","first-page":"5777","DOI":"10.1038\/s41467-024-50132-3","article-title":"Whole exome sequencing analysis identifies genes for alcohol consumption","volume":"15","author":"Kang","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.bpsgos.2026.100793_bib95","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1038\/s43587-023-00455-5","article-title":"Multivariate genome-wide analysis of aging-related traits identifies novel loci and new drug targets for healthy aging","volume":"3","author":"Rosoff","year":"2023","journal-title":"Nat Aging"},{"key":"10.1016\/j.bpsgos.2026.100793_bib96","doi-asserted-by":"crossref","first-page":"6119","DOI":"10.1038\/s41380-025-03199-3","article-title":"Genetically modeled GLP1R and GIPR agonism reduce binge drinking and alcohol-associated phenotypes: A multi-ancestry drug-target Mendelian randomization study","volume":"30","author":"Reitz","year":"2025","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.bpsgos.2026.100793_bib97","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1038\/s41467-020-16969-0","article-title":"Genetic drug target validation using Mendelian randomisation","volume":"11","author":"Schmidt","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.bpsgos.2026.100793_bib98","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s43586-021-00092-5","article-title":"Mendelian randomization","volume":"2","author":"Sanderson","year":"2022","journal-title":"Nat Rev Methods Primers"},{"key":"10.1016\/j.bpsgos.2026.100793_bib99","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-48267-2","article-title":"Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity","volume":"13","author":"Quddos","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.bpsgos.2026.100793_bib100","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/add.16679","article-title":"The association between glucose-dependent insulinotropic polypeptide and\/or glucagon-like peptide-1 receptor agonist prescriptions and substance-related outcomes in patients with opioid and alcohol use disorders: A real-world data analysis","volume":"120","author":"Qeadan","year":"2025","journal-title":"Addiction"},{"key":"10.1016\/j.bpsgos.2026.100793_bib101","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S2213-8587(22)00070-5","article-title":"Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): A substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial","volume":"10","author":"Gastaldelli","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.bpsgos.2026.100793_bib102","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S2215-0366(16)00104-8","article-title":"Neurobiology of addiction: A neurocircuitry analysis","volume":"3","author":"Koob","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.bpsgos.2026.100793_bib103","doi-asserted-by":"crossref","first-page":"811","DOI":"10.2741\/4618","article-title":"Food addiction: A common neurobiological mechanism with drug abuse","volume":"23","author":"Lindgren","year":"2018","journal-title":"Front Biosci (Landmark Ed)"},{"key":"10.1016\/j.bpsgos.2026.100793_bib104","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/j.euroneuro.2016.06.013","article-title":"Largely overlapping neuronal substrates of reactivity to drug, gambling, food and sexual cues: A comprehensive meta-analysis","volume":"26","author":"Noori","year":"2016","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.bpsgos.2026.100793_bib105","article-title":"BMI modulates calorie-dependent dopamine changes in accumbens from glucose intake","volume":"9","author":"Wang","year":"2014","journal-title":"PLOS One"},{"key":"10.1016\/j.bpsgos.2026.100793_bib106","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/jamasurg.2013.700","article-title":"Increased admission for alcohol dependence after gastric bypass surgery compared with restrictive bariatric surgery","volume":"148","author":"\u00d6stlund","year":"2013","journal-title":"JAMA Surg"},{"key":"10.1016\/j.bpsgos.2026.100793_bib107","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1093\/ije\/dyaa147","article-title":"Bariatric surgery and risk of alcohol use disorder: A register-based cohort study","volume":"49","author":"Bramming","year":"2021","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.bpsgos.2026.100793_bib108","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/s44220-025-00390-x","article-title":"An analysis on the role of glucagon-like peptide 1 receptor agonists in cognitive and mental health disorders","volume":"3","author":"De Giorgi","year":"2025","journal-title":"Nat Ment Health"},{"key":"10.1016\/j.bpsgos.2026.100793_bib109","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1097\/WNR.0000000000001071","article-title":"Accumbal ghrelin and glucagon-like peptide 1 signaling in alcohol reward in female rats","volume":"29","author":"Abtahi","year":"2018","journal-title":"NeuroReport"},{"key":"10.1016\/j.bpsgos.2026.100793_bib110","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1037\/pha0000620","article-title":"Glucagon-like peptide-1 receptors in nucleus accumbens, ventral hippocampus, and lateral septum reduce alcohol reinforcement in mice","volume":"31","author":"Allingbjerg","year":"2023","journal-title":"Exp Clin Psychopharmacol"},{"key":"10.1016\/j.bpsgos.2026.100793_bib111","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbr.2021.113726","article-title":"Differential effects of intra-ventral tegmental area ghrelin and glucagon-like peptide-1 on the stimulatory action of D-amphetamine and cocaine-induced ethanol intake in male Sprague Dawley rats","volume":"421","author":"Colvin","year":"2022","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.bpsgos.2026.100793_bib112","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s11011-014-9627-z","article-title":"Glucagon-like peptide-1 (GLP-1) receptor agonist prevents development of tolerance to anti-anxiety effect of ethanol and withdrawal-induced anxiety in rats","volume":"30","author":"Sharma","year":"2015","journal-title":"Metab Brain Dis"},{"key":"10.1016\/j.bpsgos.2026.100793_bib113","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/bcpt.13776","article-title":"Use of GLP-1 receptor agonists and subsequent risk of alcohol-related events. A nationwide register-based cohort and self-controlled case series study","volume":"131","author":"Wium-Andersen","year":"2022","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.bpsgos.2026.100793_bib114","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/dom.13522","article-title":"Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: A systematic review and individual participant data meta-analysis","volume":"21","author":"Siskind","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.bpsgos.2026.100793_bib115","doi-asserted-by":"crossref","first-page":"669","DOI":"10.3390\/biomedicines11030669","article-title":"Effect of glucagon-like Peptide-1 receptor agonists on cardio-metabolic risk factors among obese\/overweight individuals treated with antipsychotic drug classes: An updated systematic review and meta-analysis of randomized controlled trials","volume":"11","author":"Patoulias","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.bpsgos.2026.100793_bib116","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1111\/dom.14334","article-title":"The use of liraglutide 3.0 mg daily in the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first episode psychosis: Results of a pilot randomized, double-blind, placebo-controlled trial","volume":"23","author":"Whicher","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.bpsgos.2026.100793_bib117","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jad.2016.09.056","article-title":"Liraglutide promotes improvements in objective measures of cognitive dysfunction in individuals with mood disorders: A pilot, open-label study","volume":"207","author":"Mansur","year":"2017","journal-title":"J Affect Disord"},{"key":"10.1016\/j.bpsgos.2026.100793_bib118","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S2213-8587(19)30157-3","article-title":"Adjunctive liraglutide treatment in patients with persistent or recurrent type 2 diabetes after metabolic surgery (GRAVITAS): A randomised, double-blind, placebo-controlled trial","volume":"7","author":"Miras","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.bpsgos.2026.100793_bib119","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1186\/1477-7525-11-217","article-title":"Patient-reported outcomes among patients using exenatide twice daily or insulin in clinical practice in six European countries: The CHOICE prospective observational study","volume":"11","author":"Reaney","year":"2013","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.bpsgos.2026.100793_bib120","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.jhep.2024.11.028","article-title":"Metabolic dysfunction and alcohol-related liver disease (MetALD): Position statement by an expert panel on alcohol-related liver disease","volume":"82","author":"Arab","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.bpsgos.2026.100793_bib121","doi-asserted-by":"crossref","first-page":"454","DOI":"10.3390\/jpm12030454","article-title":"Sex differences in response to treatment with glucagon-like peptide 1 receptor agonists: Opportunities for a tailored approach to diabetes and obesity care","volume":"12","author":"Rentzeperi","year":"2022","journal-title":"J Pers Med"},{"key":"10.1016\/j.bpsgos.2026.100793_bib122","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1002\/oby.24360","article-title":"Efficacy and safety of GLP-1 receptor agonists, dual agonists, and Retatrutide for weight loss in adults with overweight or obesity: A bayesian NMA","volume":"33","author":"Sinha","year":"2025","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.bpsgos.2026.100793_bib123","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s00125-022-05715-4","article-title":"Management of type 2 diabetes with the dual GIP\/GLP-1 receptor agonist tirzepatide: A systematic review and meta-analysis","volume":"65","author":"Karagiannis","year":"2022","journal-title":"Diabetologia"},{"key":"10.1016\/j.bpsgos.2026.100793_bib124","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1007\/s12020-020-02394-2","article-title":"Effects of glucagon-like peptide-1 receptor agonists on fluid intake in healthy volunteers","volume":"70","author":"Winzeler","year":"2020","journal-title":"Endocrine"},{"issue":"suppl 1","key":"10.1016\/j.bpsgos.2026.100793_bib125","doi-asserted-by":"crossref","first-page":"A514","DOI":"10.1210\/jendso\/bvab048.1052","article-title":"GLP1 receptor agonists reduce fluid intake in primary polydipsia","volume":"5","author":"Winzeler","year":"2021","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.bpsgos.2026.100793_bib126","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.3390\/nu13093170","article-title":"Alcohol\u2019s impact on the gut and liver","volume":"13","author":"Pohl","year":"2021","journal-title":"Nutrients"},{"key":"10.1016\/j.bpsgos.2026.100793_bib127","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1111\/add.15147","article-title":"Alcohol use disorder and the gut","volume":"116","author":"Haber","year":"2021","journal-title":"Addiction"},{"key":"10.1016\/j.bpsgos.2026.100793_bib128","doi-asserted-by":"crossref","first-page":"944","DOI":"10.3390\/jcm14030944","article-title":"Pancreatitis risk associated with GLP-1 receptor agonists, considered as a single class, in a comorbidity-free subgroup of type 2 diabetes patients in the United States: A propensity score-matched analysis","volume":"14","author":"Ayoub","year":"2025","journal-title":"J Clin Med"},{"key":"10.1016\/j.bpsgos.2026.100793_bib132","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.addbeh.2015.06.042","article-title":"Quantifying alcohol consumption: Self-report, transdermal assessment, and prediction of dependence symptoms","volume":"50","author":"Simons","year":"2015","journal-title":"Addict Behav"},{"key":"10.1016\/j.bpsgos.2026.100793_bib133","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-080657","article-title":"Scoping review of assessment tools for, magnitudes of and factors associated with problem drinking in population-based studies","volume":"14","author":"Dagne","year":"2024","journal-title":"BMJ Open"},{"key":"10.1016\/j.bpsgos.2026.100793_bib134","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.3390\/jcm12062124","article-title":"Old and new biomarkers of alcohol abuse: Narrative review","volume":"12","author":"Fakhari","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.bpsgos.2026.100793_bib135","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1053\/j.gastro.2025.02.044","article-title":"Global consensus recommendations for metabolic dysfunction-associated steatotic liver disease and steatohepatitis","volume":"169","author":"Younossi","year":"2025","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpsgos.2026.100793_bib136","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/S2215-0366(19)30222-6","article-title":"Psychiatric comorbidities in alcohol use disorder","volume":"6","author":"Castillo-Carniglia","year":"2019","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.bpsgos.2026.100793_bib137","doi-asserted-by":"crossref","first-page":"4981","DOI":"10.1038\/s41467-020-18751-8","article-title":"Chronic glucose-dependent insulinotropic polypeptide receptor (GIPR) agonism desensitizes adipocyte GIPR activity mimicking functional GIPR antagonism","volume":"11","author":"Killion","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.bpsgos.2026.100793_bib138","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2024.171212","article-title":"GIP-derived GIP receptor antagonists\u2014A review of their role in GIP receptor pharmacology","volume":"177","author":"Rosenkilde","year":"2024","journal-title":"Peptides"},{"key":"10.1016\/j.bpsgos.2026.100793_bib139","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1152\/physrev.00053.2024","article-title":"Recent advances in alcohol metabolism: From the gut to the brain","volume":"105","author":"Goldman","year":"2025","journal-title":"Physiol Rev"},{"key":"10.1016\/j.bpsgos.2026.100793_bib140","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.2174\/0113816128292367240510111746","article-title":"A complex interplay between nutrition and alcohol use disorder: Implications for breaking the vicious cycle","volume":"30","author":"White","year":"2024","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.bpsgos.2026.100793_bib141","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.reprotox.2016.10.001","article-title":"Metabolism disrupting chemicals and metabolic disorders","volume":"68","author":"Heindel","year":"2017","journal-title":"Reprod Toxicol"},{"key":"10.1016\/j.bpsgos.2026.100793_bib142","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1001\/jama.287.19.2559","article-title":"Effects of moderate alcohol intake on fasting insulin and glucose concentrations and insulin sensitivity in postmenopausal women: A randomized controlled trial","volume":"287","author":"Davies","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.bpsgos.2026.100793_bib143","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4331\/wjbc.v6.i1.1","article-title":"Chronic alcohol consumption potentiates the development of diabetes through pancreatic \u03b2-cell dysfunction","volume":"6","author":"Kim","year":"2015","journal-title":"World J Biol Chem"},{"key":"10.1016\/j.bpsgos.2026.100793_bib144","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0324733","article-title":"Prevalence patterns of overweight and obesity in the world: An age-period-cohort analysis","volume":"20","author":"Kabir","year":"2025","journal-title":"PLoS One"},{"key":"10.1016\/j.bpsgos.2026.100793_bib145","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1002\/oby.23657","article-title":"An age-period-cohort approach to studying long-term trends in obesity and overweight in England (1992\u20132019)","volume":"31","author":"Opazo Breton","year":"2023","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.bpsgos.2026.100793_bib146","doi-asserted-by":"crossref","first-page":"e316","DOI":"10.1016\/S2468-2667(20)30062-1","article-title":"Projected prevalence and mortality associated with alcohol-related liver disease in the USA, 2019\u201340: A modelling study","volume":"5","author":"Julien","year":"2020","journal-title":"Lancet Public Health"},{"key":"10.1016\/j.bpsgos.2026.100793_bib147","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1111\/liv.15933","article-title":"Changing landscape of alcohol-associated liver disease in younger individuals, women, and ethnic minorities","volume":"44","author":"Arab","year":"2024","journal-title":"Liver Int"},{"key":"10.1016\/j.bpsgos.2026.100793_bib148","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1001\/archpsyc.61.8.807","article-title":"Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: Results from the National epidemiologic survey on alcohol and related conditions","volume":"61","author":"Grant","year":"2004","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.bpsgos.2026.100793_bib149","doi-asserted-by":"crossref","first-page":"193","DOI":"10.35946\/arcr.v39.2.09","article-title":"Pharmacotherapy for co-occurring alcohol use disorder and post-traumatic stress disorder: Targeting the opioidergic, noradrenergic, serotonergic, and GABAergic\/glutamatergic systems","volume":"39","author":"Verplaetse","year":"2018","journal-title":"Alcohol Res"},{"key":"10.1016\/j.bpsgos.2026.100793_bib150","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1111\/cts.13122","article-title":"Metabolomic alteration induced by psychotropic drugs: Short-term metabolite profile as a predictor of weight gain evolution","volume":"14","author":"Lenski","year":"2021","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.bpsgos.2026.100793_bib151","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S2215-0366(19)30416-X","article-title":"Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: A systematic review and network meta-analysis","volume":"7","author":"Pillinger","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.bpsgos.2026.100793_bib152","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1152\/ajpendo.00164.2018","article-title":"Antipsychotics and glucose metabolism: How brain and body collide","volume":"316","author":"Kowalchuk","year":"2019","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.bpsgos.2026.100793_bib153","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1001\/jamapsychiatry.2021.0005","article-title":"Association of antihypertensive drug target genes with psychiatric disorders: A Mendelian randomization study","volume":"78","author":"Chauquet","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.bpsgos.2026.100793_bib154","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1056\/NEJMoa2416394","article-title":"Tirzepatide as compared with semaglutide for the treatment of obesity","volume":"393","author":"Aronne","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bpsgos.2026.100793_bib155","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1056\/NEJMoa2504214","article-title":"Once-monthly Maridebart cafraglutide for the treatment of obesity \u2014 A Phase 2 trial","volume":"393","author":"Jastreboff","year":"2025","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"10.1016\/j.bpsgos.2026.100793_bib156","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.2337\/db24-1861-LB","article-title":"1861-LB: Efficacy and safety of HRS9531, a novel dual GLP-1\/GIP receptor agonist, in obese adults\u2014A Phase 2 trial","volume":"73","author":"Zhao","year":"2024","journal-title":"Diabetes"},{"key":"10.1016\/j.bpsgos.2026.100793_bib157","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1111\/dom.70006","article-title":"Efficacy and safety of CT-868, a novel, fully biased, dual glucagon-like peptide-1\/glucose-dependent insulinotropic polypeptide receptor agonist, in type 2 diabetes: A double-blind, randomized placebo controlled phase 2 trial","volume":"28","author":"Chakravarthy","year":"2025","journal-title":"Diabetes Obes Metab"},{"issue":"suppl 1","key":"10.1016\/j.bpsgos.2026.100793_bib158","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2337\/db23-75-LB","article-title":"CT-388, a novel once-weekly dual GLP-1 and GIP receptor modulator, is safe, well-tolerated, and produces more than 8% weight loss in four weeks in overweight and obese adults","volume":"72","author":"Chakravarthy","year":"2023","journal-title":"Diabetes"},{"issue":"suppl 1","key":"10.1016\/j.bpsgos.2026.100793_bib159","doi-asserted-by":"crossref","first-page":"142","DOI":"10.2337\/db25-142-OR","article-title":"142-OR: Safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of a dual GLP-1\/GIP receptor agonist (HDM1005)\u2014A Phase I, randomized, double-blind, placebo-controlled, single and multiple dose-escalation study","volume":"74","author":"Du","year":"2025","journal-title":"Diabetes"},{"key":"10.1016\/j.bpsgos.2026.100793_bib160","doi-asserted-by":"crossref","first-page":"E908","DOI":"10.1210\/jc.2013-3350","article-title":"Disruption of GIP\/GIPR axis in human adipose tissue is linked to obesity and insulin resistance","volume":"99","author":"Ceperuelo-Mallafr\u00e9","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bpsgos.2026.100793_bib161","doi-asserted-by":"crossref","DOI":"10.1093\/ejendo\/lvac004","article-title":"GIP reduces osteoclast activity and improves osteoblast survival in primary human bone cells","volume":"188","author":"Hansen","year":"2023","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.bpsgos.2026.100793_bib162","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.peptides.2010.12.010","article-title":"Glucose-dependent insulinotropic peptide receptor expression in the hippocampus and neocortex of mesial temporal lobe epilepsy patients and rats undergoing pilocarpine induced status epilepticus","volume":"32","author":"Figueiredo","year":"2011","journal-title":"Peptides"},{"key":"10.1016\/j.bpsgos.2026.100793_bib163","doi-asserted-by":"crossref","DOI":"10.1016\/j.appet.2022.106022","article-title":"A comparative transcriptomic analysis of glucagon-like peptide-1 receptor- and glucose-dependent insulinotropic polypeptide receptor-expressing cells in the hypothalamus","volume":"174","author":"Smith","year":"2022","journal-title":"Appetite"},{"key":"10.1016\/j.bpsgos.2026.100793_bib164","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.703966","article-title":"Distinct identity of GLP-1R, GLP-2R, and GIPR expressing cells and signaling circuits within the gastrointestinal tract","volume":"9","author":"Morrow","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.bpsgos.2026.100793_bib165","doi-asserted-by":"crossref","first-page":"G678","DOI":"10.1152\/ajpgi.00098.2013","article-title":"Glucose-dependent insulinotropic polypeptide regulates dipeptide absorption in mouse jejunum","volume":"305","author":"Coon","year":"2013","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.bpsgos.2026.100793_bib166","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/s41467-020-14309-w","article-title":"Super-resolution microscopy compatible fluorescent probes reveal endogenous glucagon-like peptide-1 receptor distribution and dynamics","volume":"11","author":"Ast","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.bpsgos.2026.100793_bib167","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1093\/eurjpc\/zwad050","article-title":"Human epicardial adipose tissue expresses glucose-dependent insulinotropic polypeptide, glucagon, and glucagon-like peptide-1 receptors as potential targets of pleiotropic therapies","volume":"30","author":"Malavazos","year":"2023","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.bpsgos.2026.100793_bib168","doi-asserted-by":"crossref","first-page":"6274","DOI":"10.1038\/s41598-019-42770-1","article-title":"Role of adipose tissue GLP-1R expression in metabolic improvement after bariatric surgery in patients with type 2 diabetes","volume":"9","author":"Ejarque","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.bpsgos.2026.100793_bib169","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s11033-025-10648-3","article-title":"Activation of GLP-1 receptors enhances the osteogenic differentiation process of STRO-1-positive BMSCs","volume":"52","author":"Zhou","year":"2025","journal-title":"Mol Biol Rep"},{"key":"10.1016\/j.bpsgos.2026.100793_bib170","doi-asserted-by":"crossref","DOI":"10.3389\/fnbeh.2021.724030","article-title":"Anatomical and functional characterization of central amygdala glucagon-like peptide 1 receptor expressing neurons","volume":"15","author":"Zeng","year":"2021","journal-title":"Front Behav Neurosci"}],"container-title":["Biological Psychiatry Global Open Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667174326001060?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667174326001060?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T08:51:13Z","timestamp":1792745473000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667174326001060"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":167,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S2667174326001060"],"URL":"https:\/\/doi.org\/10.1016\/j.bpsgos.2026.100793","relation":{},"ISSN":["2667-1743"],"issn-type":[{"value":"2667-1743","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"GLP-1 Receptor Agonist and GIP\/GLP-1 Receptor Dual Agonist Therapeutics at the Intersection of Alcohol Use Disorder, Obesity, and Cardiometabolic Dysfunction","name":"articletitle","label":"Article Title"},{"value":"Biological Psychiatry Global Open Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bpsgos.2026.100793","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc on behalf of Society of Biological Psychiatry.","name":"copyright","label":"Copyright"}],"article-number":"100793"}}